Mitogen-induced lymphocyte proliferation and systemic immune activation in cancer patients
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články
PubMed
8693596
Knihovny.cz E-zdroje
- MeSH
- aktivace lymfocytů * MeSH
- biopteriny analogy a deriváty moč MeSH
- dospělí MeSH
- fytohemaglutininy farmakologie MeSH
- interferon gama krev MeSH
- interleukin-4 krev MeSH
- konkanavalin A farmakologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory imunologie MeSH
- neopterin MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- biopteriny MeSH
- fytohemaglutininy MeSH
- interferon gama MeSH
- interleukin-4 MeSH
- konkanavalin A MeSH
- neopterin MeSH
AIMS AND BACKGROUND: Proliferative response of lymphocytes to mitogens is known to be decreased in cancer patients. Depressed proliferation of lymphocytes in other disorders has been linked to systemic inflammatory response. METHODS: Lymphocyte proliferation in response to phytohemagglutinin (PHA) and concanavalin A, as well as urinary neopterin, plasma interferon-gamma and interleukin-4, were investigated in 41 patients with solid tumors. RESULTS: The proliferative response to PHA was significantly depressed in cancer patients at most of the concentrations examined. Urinary neopterin and plasma interferon-gamma were significantly elevated in cancer patients, whereas interleukin-4 was undetectable in all the subjects. A negative correlation was observed between urine neopterin and lymphocyte proliferative response to mitogens. CONCLUSIONS: Lymphocyte proliferative response to PHA is significantly diminished in cancer patients, and this depression appears to be partly linked to systemic inflammatory response. Plasma interferon-gamma was significantly increased in cancer patients, whereas interleukin-4 was undetectable.
Neopterin as a biomarker of immune response in cancer patients